Connect with others who understand.

  •   Learn from expert-reviewed resources
  •   Real advice from people who’ve been there
  •   People who understand what you’re going through
Sign Up Log In
Powered By
Real members of MyMSTeam have posted questions and answers that support our community guidelines, and should not be taken as medical advice. Looking for the latest medically reviewed content by doctors and experts? Visit our resource section.
A MyMSTeam Member asked a question 💭
Brooklyn, NY

Does anyone know of any news in the "Remyelanation" field?!

September 21, 2017
 · 
Reactions
A MyMSTeam Member

You're most welcome anytime, I try my best to help in my family and everywhere else I can.

September 23, 2017
A MyMSTeam Member

Hi @A MyMSTeam Member, Remyelination process in Multiple Sclerosis.this is what is what I found in Remyelination, Remyelination is the phenomenon by which new myelin sheaths are generated around axons in the adult central nervous system (CNS). This follows the pathological loss of myelin in diseases like multiple sclerosis (MS). Remyelination can restore conduction properties to axons (thereby restoring neurological function) and is increasingly believed to exert a neuroprotective role on axons. Remyelination occurs in many MS lesions but becomes increasingly incomplete/inadequate and eventually fails in the majority of lesions and patients. Efforts to understand the causes for this failure of regeneration have fueled research into the biology of remyelination and the complex, interdependent cellular and molecular factors that regulate this process. Examination of the mechanisms of repair of experimental lesions has demonstrated that remyelination occurs in two major phases. The first consists of colonization of lesions by oligodendrocyte progenitor cells (OPCs), the second the differentiation of OPCs into myelinating oligodendrocytes that contact demyelinated axons to generate functional myelin sheaths. Several intracellular and extracellular molecules have been identified that mediate these two phases of repair. Theoretically, the repair of demyelinating lesions can be promoted by enhancing the intrinsic repair process (by providing one or more remyelination-enhancing factors or via immunoglobulin therapy). Alternatively, endogenous repair can be bypassed by introducing myelinogenic cells into demyelinated areas; several cellular candidates have been identified that can mediate repair of experimental demyelinating lesions. Future challenges confronting therapeutic strategies to enhance remyelination will involve the translation of findings from basic science to clinical demyelinating disease.

September 23, 2017
A MyMSTeam Member

We must buckle up the belts and wait.

September 21, 2017
A MyMSTeam Member

https://multiplesclerosisnewstoday.com/2017/05/...

September 21, 2017
A MyMSTeam Member

@A MyMSTeam Member I just got it from Walgreens online.. It's called wal-hist clemestine Fumarate tablets.. Each tab is 1.34mg clemestine or 1mg clemestine

The study was...
clemastine fumarate 5.36 mg orally twice daily for 90 days followed by placebo for 60 days (group 1), or to start with placebo for 90 days followed by active drug for 60 days (group 2) before crossing over to the other treatment arm.
About 4 times?? the normal dose I think.. I just took a 1.34 mg pill now.. I usually take benedryl.. Although I don't know if this will make me too tired to function

October 30, 2017 (edited)

Related Questions

View All
A MyMSTeam Member asked a question 💭
Saskatoon, SK

A MyMSTeam Member asked a question 💭
Menomonee Falls, WI